CTX‐4419, is a first‐in‐class NKp30xBCMA bispecific, able to induce cytokine production, NK-cell proliferation, and potent tumor cell killing of target cells, independently from high, intermediate, or low BCMA expression. This evidence concerns the gene TNFRSF17 and neoplasm.